Log in to search using one of your social media accounts:

 

Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

(University of Pennsylvania School of Medicine) The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Source: Karmanos Cancer Institute - Category: Cancer & Oncology Source Type: news
Publication date: May 2018 Source:Clinica Chimica Acta, Volume 480 Author(s): Yafang Pan, Hongmei Chen, Xianjuan Shen, Xudong Wang, Shaoqing Ju, Meihong Lu, Hui Cong Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression ...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Condition:   Multiple Myeloma Intervention:   Biological: ECT-001 (UM171) expanded cord blood Sponsors:   Ciusss de L'Est de l'Île de Montréal;   ExcellThera;   Centre de Commercialisation en Immunothérapie du Cancer (C3i) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
• Cancer cells survive via overexpressed anti-apoptotic BCL2 proteins• Venetoclax is highly selective BCL2 inhibitor with acceptable toxicity profile• It overcomes resistance to ibrutinib and idelalisib in chronic lymphocytic leukemia• Effective in a subset of multiple myeloma with high with t(11;14)• Synergic activity with low-dose cytarabine, 5-azacytidine in acute myeloid leukemia
Source: Experimental Hematology - Category: Hematology Authors: Tags: Review Source Type: research
This study shows that andrographolide inhibits the development of osteoclasts ( = the cells that chew away at our bones, which is fine in a healthy situation, not fine in cancer where everything goes nutso), while increasing the presence of osteoblasts (bone builders). The researchers say that the current therapies used to treat osteolytic diseases have many unwanted side effects. And they’re not just referring to bisphosphonates (which can cause osteonecrosis of the jaw) but also to new treatments such as the monoclonal antibody denosumab, Denosumab can cause low calcium levels, weakness, constipation, bac...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll Source Type: blogs
Haematological malignancies (leukaemias, lymphomas and myeloma) are complex cancers that are relatively common, affect all ages and have divergent outcomes. Although the symptom burden of these diseases is com...
Source: BMC Palliative Care - Category: Palliative Care Authors: Tags: Research article Source Type: research
Abstract Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression level of H19 could assist clinical staging, and the severity of the disease could be roughly determined according to the amount of H19 expressed in t...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
Conclusion Haematological malignancies in the Eastern Cape Province show disparities in gender and pathology-specific incidence patterns. The present study suggest that haematological malignancies are not uncommon in this region and the incidence rate of at least one rare subtype, APL, is comparable with some European populations.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
d R Abstract In normal cells, aberrant oncogene expression leads to the accumulation of cytotoxic metabolites, including reactive oxygen species (ROS), which can cause oxidative DNA-damage and apoptosis as an intrinsic barrier against neoplastic disease. The c-Myc oncoprotein is overexpressed in many lymphoid cancers due to c-myc gene amplification and/or 8q24 chromosomal translocations. Intriguingly, p53 is a downstream target of c-Myc and hematological malignancies, such as adult T-cell leukemia/lymphoma (ATL), frequently contain wildtype p53 and c-Myc overexpression. We therefore hypothesized that p53-regulated...
Source: Virology - Category: Virology Authors: Tags: Virology Source Type: research
Publication date: 10 May 2018 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 153 Author(s): Yashpal S. Chhonker, Staci L. Haney, Robert A. Matthiesen, David F. Wiemer, Sarah A. Holstein, Daryl J. Murry An isomeric mixture of homogeranyl/homoneryl triazole bisphosphonates (VSW1198) has previously been shown to be a potent inhibitor of geranylgeranyl diphosphate (GGDP) synthase (GGDPS) and of therapeutic interest for the treatment of multiple myeloma. We have developed and validated a selective and sensitive liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) method for the simulta...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Myeloma | Toxicology | University of Pennsylvania